CRSP

39.0900.41%
CC

Craig C. Mello

Scientific Founder & Advisory Board Member

Dr. Craig C. Mello, Ph.D., is Scientific Founder & Advisory Board Member of CRISPR Therapeutics, Inc. Dr. Mello is the Chairman of Scientific Advisory Board at Comanche Biopharma Corp. He serves as Member of Advisory Board at AgroSpheres, Inc. Dr. Mello serves as Chairman of the Scientific Advisory Board at hC Bioscience, Inc. since February 2022. He served as the Co-Founder & Scientific Advisor of Atalanta Therapeutics until December 2025. Dr. Mello is the Founder of RXi Pharmaceuticals Corporation and served as its Chairman of Scientific Advisory Board since February 2007. Dr. Mello serves as Scientific Founder and Advisory Board Member of CRISPR Therapeutics AG. Dr. Mello co-founded Galena Biopharma, Inc. and served as its Chairman and Member of the Scientific Advisory Board since February 2007. Dr. Mello served as a Scientific Advisor of Sequitur Inc. Dr. Mello serves as a Member of Technology Advisory Board at Beeologics, LLC. Dr. Mello has been Director of Grove Instruments Inc. since January 01, 2012 and Member of Scientific Advisory Board. Dr. Mello serves as a Member of Scientific Advisory Boards for Araios, Inc., a subsidiary of CytRx Corporation. Dr. Mello serves as Co-director of RNA Therapeutics Institute at University of Massachusetts Medical School, Worcester, MA. Dr. Mello served as a Member of Scientific Advisory Boards for CytRx Corporation and also for CytRx Laboratories Inc. He serves as Blais University Chair and Distinguished Professor of Molecular Medicine and a Howard Hughes Medical Institute Investigator at the University of Massachusetts Medical School, in Worcester, Massachusetts. Dr. Mello, co-recipient of the 2006 Nobel Prize in Physiology or Medicine for RNAi, co-discovered RNAi and co-invented RNAi therapeutics. Dr. Mello uses C. elegans to study both the biochemical pathway responsible for RNAi and the regulation of gene expression in early embryogenesis. Dr. Mello has numerous publications credits including 16 in the prestigious journals Science, Nature, Cell and the Proceedings of the National Academy of Sciences. He was the co- discoverer of the revolutionary RNA interference technology (RNAi), also known as, 'gene silencing'. Dr. Mello, of the University of Massachusetts Medical School, is a key inventor on the first approved patent for the use of double stranded RNA for gene silencing, a technology that has to be known as RNAi. In 2003, Dr. Mello shared the Wiley Foundation Prize and the prestigious National Academy of Sciences Award in Molecular Biology with Dr. Fire for their work on RNAi. Dr. Mello's pioneering research on RNAi, has also been recognized with the prestigious National Academy of Sciences Molecular Biology Award, the Wiley Prize in the Biomedical Sciences from Rockefeller University in 2003, The MGH Warren Triennial Prize, the Rosenstiel Award, the Gairdner Foundation International Award, the Massry Prize, the Paul Ehrlich and Ludwig Darmstaedter Prize and the first Paul Janssen Award for Biomedical Research by Johnson & Johnson in 2006. From 1990 to 1994, he conducted postdoctoral research at the Fred Hutchinson Cancer Research Center in Seattle, WA. In 1995, he was named a Pew Scholar in the Biomedical Sciences. He is a member of the National Academy of Sciences, the American Academy of Arts and Sciences and the American Philosophical Society. Prior to joining the University of Massachusetts Medical School, Dr. Mello was a Post-Doctoral Fellow in the lab of Dr. Jim Priess at the Fred Hutchinson Cancer Research Center at the University of Washington in Seattle. Dr. Mello received his B.Sc. degree in Biochemistry from Brown University in 1982 and received his Ph.D. in Cellular and Developmental Biology from Harvard University in 1990. He also conducted Graduate Studies in the Laboratory of David Hirsh, Ph.D., at University of Colorado. He had been a Member of the Scientific Advisory Board of Divergence, Inc. since 2001.

Positions